Tempus Ai, Inc. · NASDAQ:TEM
Tempus Ai — Technical Presentation (March 2025)
14 slides from Tempus Ai's technical presentation, March 2025
Slide 1: Investigating the Clinical Landscape and Biological Impact of SF3B1 Hotspot Mutations In Breast Cancer
Investigating the Clinical Landscape and Biological Impact of SF3B1 Hotspot Mutations In Breast Cancer Riley Bergman Mentored by Ben Ho Park, MD/PhD Medical Scientist Training Program and Program in Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
Slide 2: Disclosure Information
Disclosure Information I have no financial relationships to disclose.
Slide 3: SF3B1 Mutations are Poorly Understood in Breast Cancer
SF3B1 Mutations are Poorly Understood in Breast Cancer Current limitations: Much of what we know is derived from heme malignancies Widespread changes 🡪 Lack of consensus on the role(s) of SF3B1 in cancer Relatively low representation in clinical datasets This study investigates the genetic profile,
Slide 4: SF3B1 Mutations are Poorly Understood in Breast Cancer
SF3B1 Mutations are Poorly Understood in Breast Cancer Current limitations: 1. Much of what we know is derived from heme malignancies 2. Widespread changes 🡪 Lack of consensus on the role(s) of SF3B1 in cancer 3. Relatively low representation in clinical datasets This study investigates the genetic
Slide 5: Analysis of SF3B1 Mutations and Survival in Breast Cancer Patients
Analysis of SF3B1 Mutations and Survival in Breast Cancer Patients Breast cancer patients Molecular profiling Retrospective review with SF3B1 hotspot with of De-identified mutations (N = 218) Tempus xT assay* patient data +
Slide 6: Analysis of SF3B1 Mutations and Survival in Breast Cancer Patients
Analysis of SF3B1 Mutations and Survival in Breast Cancer Patients Breast cancer patients Molecular profiling Retrospective review with SF3B1 hotspot with of De-identified mutations (N = 218) Tempus xT assay* patient data + SF3B1 hotspot Hazard ratio (HR) was calculated mutation using Cox proportion
Slide 7: SF3B1 K700E Mutations are Enriched in HR+ HER2- Breast Cancer
SF3B1 K700E Mutations are Enriched in HR+ HER2- Breast Cancer
Slide 8: Improved rwOS in Patients with SF3B1 Mutant HR+, HER2- Breast Cancer
Improved rwOS in Patients with SF3B1 Mutant HR+, HER2- Breast Cancer Overall survival of patients with HR+/HER2- breast cancer Unpublished – please do not post/photograph
Slide 9: Generation of an SF3B1 mutant Isogenic Cell Line Panel
Generation of an SF3B1 mutant Isogenic Cell Line Panel
Slide 10: SF3B1 Mutations Lead to Poor Growth
SF3B1 Mutations Lead to Poor Growth In-vitro growth of MCF7 SF3B1 In-vivo growth of MCF7 SF3B1 mutant mutant clones clones as orthotopic xenografts Unpublished – please do not post/photograph
Slide 11: SF3B1 Mutations are Associated with Lower Proliferative Indices
SF3B1 Mutations are Associated with Lower Proliferative Indices Unpublished – please do not post/photograph
Slide 12: SF3B1 Mutations Undergo Negative Selection in-vitro and Variation in Mutant VAF is Observed Clinically
SF3B1 Mutations Undergo Negative Selection in-vitro and Variation in Mutant VAF is Observed Clinically VAF in MCF7 SF3B1 Mutants Across Cell Passages, Variation in VAF for SF3B1 Driver Mutations in measured by droplet digital PCR Advanced Breast Cancer Unpublished – please do not post/photograph
Slide 13: Ongoing efforts to define molecular consequences and therapeutic opportunities
Ongoing efforts to define molecular consequences and therapeutic opportunities The most comprehensive cell panel & largest clinical cohort of patients with SF3B1 mutant breast cancer to date shows: • Improved rwOS in patients with SF3B1 mutations • Poor cell growth with negative selection These find
Slide 14: Acknowledgments
Acknowledgments Vanderbilt Groups Tempus Collaborators Funding: • Park Lab • Tina M. O’Grady, PhD • F30CA268325 • Ben Park, MD PhD • Yingying Yu, MHS • T32GM007347 • Sarah Croessmann, PhD • Stamatina Fragkogianni, PhD • PEO Scholar Award • Sarah Reed • Amrita A. Iyer, PhD • Bryce Thomas • All of the